Cast versus functional brace in the rehabilitation of patients treated non-operatively for a rupture of the Achilles tendon: protocol for the UK study of tendo achilles rehabilitation (UK STAR) multi-centre randomised trial by Achten, Juul et al.
 1Achten J, et al. BMJ Open 2017;7:e019628. doi:10.1136/bmjopen-2017-019628
Open Access 
AbstrAct
Introduction Achilles tendon rupture affects over 11 000 
people yearly in the UK, and the incidence is increasing. 
Controversy remains with regard to the best rehabilitation 
strategy for these patients. In operatively treated patients, 
functional bracing provides better outcomes compared 
with plaster casts. However, the role of functional bracing 
in non-operatively managed patients is unclear. This is the 
protocol for a multicentre randomised trial of plaster cast 
immobilisation versus functional bracing for patients with 
a non-operatively managed Achilles tendon rupture. 
Methods and analysis All adults presenting with a 
primary rupture of the Achilles tendon will be screened. 
Non-operatively treated patients will be eligible to take 
part in the trial. Broad eligibility criteria will ensure that 
the results of the study can be generalised to the wider 
patient population. Randomisation will be on a 1:1 basis. 
Both rehabilitation strategies are widely used within the 
National Health Service. Standardised protocols will be 
followed, and details of plaster material and brace will 
be as per the site’s usual practice.   A minimum of 330 
patients will be randomised to obtain 90% power to detect 
a difference of 8 points in Achilles Tendon Total Rupture 
Score at 9 months. Quality of life and resource use will be 
collected at 3, 6 and 9 months. The differences between 
treatment groups will be assessed on an intention-to-treat 
basis. The results of the trial-based economic evaluation 
will be expressed in terms of incremental cost per quality-
adjusted life-year gained. 
Ethics and dissemination The National Research Ethic 
Committee approved this study on 18 March 2016 (16/
SC/0109).  The National Institute for Health Research 
Health Technology Assessment monograph and a 
manuscript to a peer-reviewed journal will be submitted 
on completion of the trial (summer 2019). The results of 
this trial will substantially inform clinical practice on the 
clinical and cost-effectiveness of the treatment of this 
injury. This study has been registered on the International 
Standard Randomised Controlled Trial Number registry 
with reference no ISRCTN62639639.
bAckground
The Achilles tendon is the largest tendon in 
the human body and transmits the powerful 
contractions of the calf muscles that are 
required for walking and running. When 
the tendon ruptures, it is painful and has an 
immediate and serious detrimental impact on 
daily activities of living.1 In the longer-term, 
tendon rupture results in prolonged periods 
off work and time away from sporting activity: 
average time away from work is between 4 and 
8 weeks and time away from sport is between 
26 and 39 weeks.1 This results in lost income 
and restricted daily activities in the early phase 
and reduced physical activity, with associated 
negative health and social consequences, in 
the long-term. For high-level sportsmen, it is 
frequently a ‘career-ending’ injury.
Achilles rupture affects over 11 000 
people each year in the UK, and the inci-
dence is increasing as the population 
remains more active into older age.2 It 
affects all age groups in a bimodal distri-
bution; with the first peak in patients 
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Protocol
strengths and limitations of this study
 ► Broad eligibility criteria to ensure generalisability.
 ► Patient-centred outcomes in combination with 
complication data will be collected.
 ► Assessment of outcomes at multiple time points will 
allow for information on recovery profile.
 ► In addition to a comparison of clinical outcomes, a 
full cost evaluation will be performed.
 ► It will not be possible to blind patients to their 
allocated treatment, as the plaster cast/walking boot 
will be clearly visible.
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aged 30–40 years and the second 60–80 years.2 The 
first peak in incidence is often associated with partic-
ipation in sport, such as football and racquet sports, 
whereas the second peak often occurs during normal 
daily activities, such as climbing stairs.2 However, all 
Achilles ruptures are associated with a pre-existing 
‘tendinopathy’ which is attributed to failures in the 
protective/regenerative functions which respond to 
repeated microscopic injury.3 4
Traditionally, patients have been treated in plaster 
casts after rupture of the Achilles; with the cast 
immobilising the foot and ankle while the tendon 
heals. However, there are potential problems with 
this approach. First, there is the immediate impact 
on mobility for a period of around 8 weeks. Second, 
there are the complications and risks associated with 
prolonged immobilisation: muscle atrophy, deep vein 
thrombosis and joint stiffness.5 6 Finally, there are 
the potential long-term consequences which include 
prolonged gait abnormalities, persistent calf muscle 
weakness and an inability to return to previous activity 
levels.7 Functional bracing, involving immediate, 
protected weight-bearing in an orthotic, was designed 
to address these issues.
In patients having a surgical repair, seven RCTs1 8–13 
were conducted, directly comparing plaster casts with 
early movement and/or weight-bearing in a ‘func-
tional brace’. The results favour functional bracing 
in terms of re-rupture rate, functional outcome and 
quality of life measures. Therefore, in the first guide-
line (2009) produced on this topic, the American 
Academy of Orthopaedic Surgeons recommended 
functional bracing for patients having surgical repair 
of their tendon.14
We supplemented the 2004 Cochrane review15 
with an updated literature search and found that in 
total only two studies16 17 been performed comparing 
the use of functional bracing with plaster casts for 
patients managed non-operatively following rupture 
of the Achilles tendon. Both studies suggested poten-
tial benefits from bracing. However, the data from the 
studies should be interpreted with caution owing to 
small patient numbers (90 in total), patients having 
received different functional bracing regimes and 
minimal reporting of outcomes. The gap in the 
evidence was recognised in the recent American 
Academy of Orthopaedic Surgeons, guideline 200914 
which concluded that ‘For patients treated non-oper-
atively, we are unable to recommend for or against 
the use of immediate functional bracing for patients 
with acute Achilles tendon rupture’. Does functional 
bracing provide improved function and quality of 
life if the tendon is not surgically repaired? Or, in 
the context of a tendon that has not been stitched 
together, does a plaster cast provide greater protec-
tion and therefore improved healing? Does func-
tional bracing facilitate faster return to work and is 
this cost effective? Or, is the tendon more vulnerable 
to re-rupture in a brace with the subsequent risk and 
cost of reconstructive surgery?
good clinical practice
The trial will be carried out in accordance with the Medical 
Research Council Good Clinical Practice and applicable 
UK legislation using the following protocol.
consort
The trial will be reported in line with the CONSORT state-
ment using the non-pharmacological treatment interven-
tions extension.
trial design
Aim
The aim of this project is to improve functional outcome 
by determining the best rehabilitation strategy for non-op-
eratively managed patients with a rupture of the Achilles 
tendon.
Objectives
The primary objective is: to quantify and draw inferences 
on observed differences in Achilles Tendon Total Rupture 
Score (ATRS) between the trial treatment groups at 9 
months after injury.
The secondary objectives are:
1. To quantify and draw inferences on observed 
differences in ATRS between the trial treatment 
groups at 8 weeks and 3 and 6 months after the injury,
2. To identify any differences in health-related quality of 
life between the trial treatment groups in the first 9 
months after the injury,
3. To determine the complication rate between the trial 
treatment groups in the first 9 months after the injury,
4. To investigate, using appropriate statistical and 
economic analytical methods, the resource use, costs 
and comparative cost-effectiveness between the trial 
treatment groups.
outcome measures
The primary outcome measure for this study is the 
ATRS.18 The ATRS is a validated questionnaire which is 
self-reported. It consists of 10 items assessing symptoms 
and physical activity specifically related to the Achilles 
tendon. It measures: strength, fatigue, stiffness, pain, 
activities of daily living, walking on uneven surfaces, 
walking upstairs or uphill, running, jumping and physical 
labour. This data will be collected at baseline, 8 weeks and 
3, 6 and 9 months postrandomisation. The ATRS reaches 
a plateau between 6 and 9 months after rupture.19 The 
validity and reliability of this outcome measure has been 
previously published.18 20
The secondary outcome measures in this trial are:
Euroqol-5D: The EQ-5D-5L is a validated, generic 
health-related quality of life measure consisting of 5 
dimensions each with a 5-level answer possibility. The 
EQ-5D can be used to report health-related quality of life 
in each of the five dimensions, and each combination of 
answers can be converted into a health utility score.21 It 
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has good test–retest reliability, is simple for patients to use 
and gives a single preference-based index value for health 
status that can be used for broader cost-effectiveness 
comparative purposes. This data will be collected at base-
line, 8 weeks and 3, 6 and 9 months postrandomisation.
Complications: All complications will be recorded, from 
the medical records at the 8-week review and self-reported 
by the patient thereafter. This data will be collected at 8 
weeks and 3, 6 and 9 months postrandomisation.
sample size
The primary outcome for this study is the ATRS18. This 
is a 10-question, patient reported, outcome measure 
designed for patients with an Achilles tendon rupture. 
The individual items are converted to a 100-point scale 
where ‘0’ represents complete disability and ‘100’ is 
normal function. We have chosen a minimum clini-
cally important difference (MCID) for the ATRS of 8 
points.20 At an individual patient level, a difference of 8 
points represents the ability to walk upstairs or run with 
‘some difficulty’ versus with ‘great difficulty’. At a popu-
lation level, 8 points represents the difference between a 
‘healthy patient’ and a ‘patient with a minor disability’.20
The SD of the ATRS 9 months after injury in previous 
work was 20 points19; with an approximately normal 
distribution.
Based on this current knowledge, 264 patients repre-
sent the most likely scenario for 90% power to detect the 
selected MCID; representing a standardised effect size of 
0.4.
Allowing a margin of 20% loss of primary outcome data, 
we propose to recruit a minimum of 330 patients in total. 
The 20% loss of data will include patients who cross-over 
between interventions and those who are lost to follow-up. 
Therefore, a minimum of 165 patients randomised to 
each group will provide 90% power to detect a difference 
of 8 points in ATRS at 9 months at the 5% level.
Methodology
Screening
All adult patients presenting within 14 days of a primary 
(first-time) rupture of the Achilles tendon will be screened 
by the clinical care team in a minimum of 20 National 
Health Service (NHS) trust in the UK. The patient, in 
conjunction with their surgeon, will decide if they have 
surgery or not. If they decide not to have surgery (non-op-
erative treatment), they will be eligible to take part in the 
trial and will be referred to the research team.
Screening logs will be collected throughout the trial to 
assess the main reasons for patient exclusion as well as 
number of patients unwilling to take part.
Eligibility
Patients will be considered for participation in this study 
if:
They are aged 16 years or older.
They have a primary rupture of the Achilles tendon.
They have decided to have non-operative treatment.
Patients will be excluded from participation in this 
study if they:
Present to the treating hospital more than 14 days after 
the injury,
There is evidence that the patient would be unable to 
adhere to trial procedures or complete questionnaires; for 
example, a history of permanent cognitive impairment.
The first exclusion criterion relates to patients with 
‘late presentation’, which is not uncommon after this 
injury. Patients who present late may have problems with 
chronic tendon lengthening irrespective of treatment 
and are frequently offered surgical intervention. The 
‘14 days’ has been widely used to define ‘acute’ rupture, 
including in our own pilot work.
The second criterion reflects the fact that much of the 
outcome data is collected by postal or electronic ques-
tionnaire, when help and support will not be available. 
Also, the primary outcome measure is not validated for 
proxy reporting.
If a patient taking part in the study were to sustain a 
contralateral rupture during the trial period, the second 
rupture would not be included in the study because the 
result of this intervention would not be independent 
from the first intervention. However, the patient would 
remain in the trial, with both previous and future data 
related to the initial rupture included in the final analysis.
Consent
Informed consent from the patient will be obtained by 
an appropriately trained and delegated member of the 
research team. Patients will be provided with verbal and 
written information about the study. Patients will be asked 
to consent to long-term follow-up and data linkage to 
routine NHS datasets.
Randomisation
The 1:1 allocation to either functional bracing or 
plaster cast will be generated by the trial statistician and 
concealed using a secure, centralised, computer-gener-
ated allocation sequence and web-based randomisation 
service. The Research Associate will inform the treating 
clinical team of the allocated treatment.
Stratification by centre will help to ensure that any effect 
related to the centre itself will be equally distributed in 
the trial arms. The catchment area will be similar for all of 
the hospitals; each hospital is a trauma unit dealing with 
these injuries on a daily basis. While unlikely, it is possible 
that the clinicians at one centre may be more expert in 
one or other treatment than those at another centre. 
Therefore, all of the recruiting hospitals have been/will 
be chosen on the basis that both techniques are currently 
routinely available at the centre, that is, the clinical staff 
are already familiar with both plaster casts and functional 
bracing.
Postrandomisation withdrawals
Participants may decline to continue to take part in the 
trial at any time without prejudice. A decision to decline 
group.bmj.com on December 19, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
4 Achten J, et al. BMJ Open 2017;7:e019628. doi:10.1136/bmjopen-2017-019628
Open Access 
consent or withdraw will not affect the standard of care 
the patient receives.
Participants have two options for withdrawal:
1. Participants may withdraw from completing any 
further questionnaires but allow the trial team to still 
view and record anonymously any relevant hospital 
data that is recorded as part of normal standard of 
care.
2. Participants can withdrawal wholly from the study, and 
only data obtained up until the point of withdrawal 
will be included in the final analysis of the study, 
thereafter no further data will be collected for that 
participant.
Withdrawn participants will not be replaced as the 
sample size calculation has allowed for loss to follow-up.
Blinding
As the type of rehabilitation used is clearly visible, the 
patients cannot be blind to their treatment. In addition, 
the treating clinician will also not be blind to the treat-
ment but will take no part in the posttreatment assess-
ment of the patients. The outcome data will be collected 
and entered onto the trial central database via question-
naire, by a research assistant/data clerk in the trial central 
office to reduce the risk of assessment bias.
trial treatments
Following randomisation, one group of patients will 
receive a plaster cast, and one group will receive a func-
tional brace. All of the hospitals involved in this trial 
currently use both plaster casts and functional bracing for 
patients with both soft tissue injuries (tendon and liga-
ment) and fractures, so all clinicians/units are familiar 
with both interventions.
Although the principles of application of both plaster 
casts and functional bracing are inherent in the tech-
nique, there are different types of plaster cast material 
and functional brace design. Each patient will undergo 
the allocated intervention according to the protocol 
below, but the details of the plaster and brace will be left 
to the discretion of the treating clinician, as per their 
usual practice. This will ensure that the results can be 
generalised across the NHS.
Plaster cast
The initial plaster cast will be applied in the ‘gravity 
equinus’ position, that is, the position that the foot natu-
rally adopts when unsupported. In this position, with the 
toes pointing down towards the floor, the ends of the 
ruptured tendon are roughly approximated. Some units 
may use ultrasound to assess the approximation of the 
tendon ends, but this is not routine22 and so will be left 
to the discretion of the treating clinician. The patient 
may mobilise with crutches immediately using their toes 
for balance (toe-touch), but patients are not able to bear 
weight on the injured hindfoot. Over the first 8 weeks, 
as the tendon heals, the position of the plaster cast is 
changed until the foot achieves ‘plantargrade’, that is, 
the foot is flat to the floor. At this point, the patient may 
start to bear weight in the plaster cast. The number of 
changes of plaster cast and the time to weight-bearing 
will be left to the discretion of the treating clinician, as 
per their usual practice. The cast will be removed at 8 
weeks.
The plaster cast provides maximum protection for the 
healing tendon, specifically it restricts the upward (dorsi-
flexion) movement of the ankle which may stretch the 
healing tendon, but it does not allow the patient to bear 
weight on the foot immediately.
Functional bracing
A rigid brace will be used in the trial, as opposed to a 
flexible brace.23 Initially, two 1 cm heel solid wedges (or 
equivalent) will be inserted into the brace to replicate 
the ‘gravity equinus’ position of the foot.24 The patient 
may mobilise with immediate full weight-bearing within 
the functional brace. The number of wedges/foot posi-
tion will then be reduced until the patient reaches ‘plan-
tigrade’. Again, the timing of the removal of wedges/
change in foot position will be left to the discretion of the 
treating clinician, as per their usual practice. The brace 
will be removed at 8 weeks.
The functional brace does not provide the same restric-
tion of movement as the cast but does allow the patient to 
bear weight on the foot immediately.
Rehabilitation
When the cast/brace is removed after 8 weeks, we will 
provide all patients (both groups) with the same stan-
dardised, written physiotherapy advice detailing the exer-
cises they need to perform for rehabilitation following 
their injury. This will be based on a published system-
atic review of current rehabilitation protocols.24 All 
of the patients in both groups will be advised to move 
their toes, ankle and knee joints fully within the limits 
of their comfort, and walking will be encouraged. In this 
pragmatic trial, any other rehabilitation input beyond 
the written physiotherapy advice (including a formal 
referral to physiotherapy) will be left to the discretion 
of the treating clinicians. However, a record of any reha-
bilitation input (type and number of additional appoint-
ments) as well as other investigations/interventions will 
be requested as part of the 8-week, 3-month, 6-month and 
9-month follow-up questionnaires.
Adverse event management
Adverse events will be listed on the appropriate Case 
Report Form for routine return to the ‘UK STAR’ central 
office. Serious adverse events (SAEs) will be entered onto 
the SAE reporting form and reported to the central study 
team. However, some adverse events are foreseeable as 
part of the proposed treatment and will not be reported 
on an SAE reporting form but recorded on a complica-
tions form. These events include: re-rupture, blood clots/
emboli, pressure areas/hindfoot pain, falls and neurolog-
ical symptoms in the foot.
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All participants experiencing SAEs will be followed-up 
as per protocol until the end of the trial. All unexpected 
SAEs that occur between date of consent and 9-month 
follow-up point will be reported to the sponsor and ethics 
committee.
End of trial
The end of the trial will be defined as the collection of 9 
months outcome data from the last participant.
statistical analysis
Results reporting will be in accordance with the 
CONSORT extension for non-pharmacological interven-
tions.25 Primary analysis will be conducted on an inten-
tion-to-treat basis to compare the treatment arms in terms 
of the ATRS at 9 months after surgery. Early functional 
status will also be assessed and reported at 8 weeks and 3 
and 6 months. Baseline characteristics will be summarised 
with descriptive statistics, presented for both treatment 
arms and overall.
We do not expect age or gender to influence the treat-
ment effects, based on the results of our pilot work.20 
However, the main findings of the trial will be reported 
as the difference on the ATRS between treatment arms, 
estimated with a linear mixed effects (LME) regression 
model, including outcome information from all follow-up 
points and adjusting for these and other potentially 
important prognostic variables. As individual clinicians 
will treat only a small number of patients, important 
clinician-specific effects are not expected; but, recruiting 
centre will be included in the model as a random effect 
factor to adjust for potential cluster differences. Esti-
mates of treatment effects will be presented with 95% 
CIs. All statistical tests will be two-sided and considered 
to provide strong enough evidence to support differences 
between treatments if p values are smaller than 0.05 (5% 
significance level). Where severe departure from normal 
distribution is identified, data transformation will be 
endeavoured. If normality cannot be achieved, compar-
isons will be done using non-parametric tests without 
adjustment. Secondary continuous outcomes will be 
analysed using the same methods applied to the primary 
outcome.
All available data from both treatment arms will be used 
in the analysis. Although high amounts of missing data 
are not expected, its nature and pattern will be carefully 
considered. LME regression models have the advantage 
of producing robust estimates when data is missing at 
random. Nevertheless, missing data multiple imputation 
will be implemented if judged appropriate. In this case, 
sensitivity analysis will be conducted with the resulting 
imputed datasets. Reasons for ineligibility, withdrawal, 
non-compliance or other protocol violations will be 
described, and any patterns summarised. A detailed statis-
tical analysis plan will be agreed early in the trial, and any 
subsequent amendments will be clearly stated and justified 
in the final study report. Interim analysis of the outcomes 
is not planned and will only be undertaken where directed 
by the independent data monitoring committee. Statis-
tical analysis will be performed using validated statistical 
packages such as Stata (v14.2 or higher, www. stata. com) 
or R (www. r- project. org/).
Health economic analysis
A prospective economic evaluation, conducted from an 
NHS and personal social services perspective, will be inte-
grated into the trial design. The economic evaluation 
will estimate the difference in the cost of resource inputs 
used by participants in the two arms of the trial, allowing 
comparisons to be made between the two non-surgical 
treatment options (plaster cast vs functional bracing) 
for patients with a primary (first-time) rupture of the 
Achilles tendon and enabling costs and consequences 
to be compared. The economic assessment method will, 
as far as possible, adhere to the recommendations of the 
National Institute for Health and Care Excellence (NICE) 
Reference Case.26
Primary research methods will be followed to estimate 
the costs of the treatment options, including supplemen-
tary interventions (eg, surgery) and rehabilitation inputs. 
Broader resource utilisation will be captured through to 
principal sources: (1) routine health service data collec-
tion systems and (2) patient questionnaires administered 
at baseline, 8 weeks and 3, 6 and 9 months postrandomis-
ation. Unit costs for health and social care resources will 
largely be derived from local and national sources and esti-
mated in line with best practice. Primary research using 
established accounting methods may also be required to 
estimate unit costs. Costs will be standardised to current 
prices where possible. Health-related quality of life will 
be measured at baseline preinjury, at the time of consent, 
8 weeks and 3, 6 and 9 months postrandomisation using 
the EuroQol EQ-5D-5L measure; responses will be used 
to generate quality-adjusted life-years (QALYs). Utility 
weights will be estimated using recommended algorithms 
until a national tariff set for the EQ-5D-5L is available.21 
We will in the first instance use self-reports of the EQ-5D 
measure. Where these data are not available, we will esti-
mate health utilities at each time point using mapping 
equations between the ATRS and EQ-5D health outcomes 
on the basis of existing datasets held by the trial team.
Multiple imputation methods will be used to impute 
missing data and avoid biases associated with complete 
case analysis. The results of the economic evaluation 
will be expressed in terms of incremental cost per QALY 
gained. We shall use non-parametric bootstrap estimation 
to derive 95% CIs for mean cost differences between the 
trial groups and to calculate 95% CIs for incremental 
cost--effectiveness ratios. A series of sensitivity analyses 
will be undertaken to explore the implications of uncer-
tainty on the incremental cost-effectiveness ratios and to 
consider the broader issue of the generalisability of the 
study results. One such sensitivity analysis will involve 
adopting a societal perspective for the economic evalu-
ation, which will incorporate direct costs to trial partici-
pants, informal care provided by family and friends and 
group.bmj.com on December 19, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
6 Achten J, et al. BMJ Open 2017;7:e019628. doi:10.1136/bmjopen-2017-019628
Open Access 
productivity losses. In the baseline analysis, and for each 
sensitivity analysis, cost-effectiveness acceptability curves 
will be constructed using the net-benefits approach. 
Heterogeneity in the trial population will be explored by 
formulating net-benefit values for trial participants from 
the observed costs and effects and then constructing a 
regression model with an intervention variable and covari-
ates such as age and sex. The magnitude and significance 
of the coefficients on the interactions between the covari-
ates and the intervention variable will provide estimates of 
cost-effectiveness of the treatment options by participant 
subgroup. More extensive economic modelling using 
decision-analytic methods will extend the target popula-
tion, time horizon and decision context, drawing on best 
available information from the literature together with 
stakeholder consultations to supplement the trial data. 
Parameter uncertainty in the decision-analytic model 
will be explored using probabilistic sensitivity analysis. 
Longer-term costs and consequences will be discounted 
to present values using discount rates recommended for 
health technology appraisal in the UK.
trial oversight
The day-to-day management of the trial will be the 
responsibility of the Clinical Trial Manager, based at Nuff-
ield Department of Orthopaedics, Rheumatology and 
Musculoskeletal Sciences and supported by the Oxford 
Clinical Trials Research Unit staff. This will be overseen 
by the Trial Management Group, who will meet monthly 
to assess progress. It will also be the responsibility of 
the Clinical Trial Manager to undertake training of the 
research associates at each of the trial centres. The Trial 
Statistician and Health Economist will be closely involved 
in setting up data capture systems, design of databases 
and clinical reporting forms.
A Trial Steering Committee (TSC) and a Data and 
Safety Monitoring Committee (DSMC) will be set up. The 
study DSMC will adopt a DAMOCLES (DAta MOnitoring 
Committees: Lessons, Ethics, Statistics) charter which 
defines its terms of reference and operation in relation to 
oversight of the trial. They will not be asked to perform 
any formal interim analyses of effectiveness. They will, 
however, see copies of data accrued to date or summaries 
of that data by treatment group, and they will assess the 
screening algorithm against the eligibility criteria. They 
will also consider emerging evidence from other related 
trials or research-related and review-related SAEs that 
have been reported. They may advise the chair of the TSC 
at any time if, in their view, the trial should be stopped 
for ethical reasons, including concerns about partici-
pant safety. DSMC meetings will be held at least annually 
during the recruitment phase of the study.
Quality control
The study may be monitored or audited in accordance 
with the current approved protocol, relevant regulations 
and standard operating procedures by the host organi-
sation, sponsor or appropriate regulatory authorities. 
A monitoring plan will be developed according to the 
OCTRU standard operating procedures which involve 
a risk assessment. The monitoring activities are based 
on the outcome of the risk assessment and may involve 
central monitoring and site monitoring.
Ethics and dissemination
The National Research Ethic Committee approved this 
study on 18 March 2016 (16/SC/0109).
The study monograph for the National Institute for 
Health Research Health Technology Assessment will be 
prepared by the trial management team within 3 months 
of completion of the trial. A manuscript for a high impact 
peer-reviewed journal will be prepared simultaneously, 
which will allow for the results to be disseminated across 
the orthopaedic and rehabilitation communities, the 
wider medical community, NICE and policy-makers. 
Authorship will be determined in accordance with the 
International Committee of Medical Journal Editors 
guidelines, and other contributors will be acknowledged. 
The results of this trial will substantially inform clinical 
practice on the clinical and cost-effectiveness of the 
treatment of this injury. The results of this project will 
be disseminated to patients via patient-specific newslet-
ters and through local mechanisms at all participating 
centres.
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